Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Letters to the Editor

In Reply: Antiobesity drug therapy

Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657-658; DOI: https://doi.org/10.3949/ccjm.88c.12002
Yael Mauer
Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Marcie Parker
Ambulatory Care Clinical Specialist, Department of Pharmacy, Cleveland Clinic, Beachwood, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sangeeta Kashyap
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case, Western Reserve University; Associate Program Director, Endocrinology, Diabetes, and Metabolism Fellowship Cleveland Clinic Cleveland, OH Associate Editor,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

In Reply: I thank Dr. Modarressi for these comments and agree that the impact of many glucagon-like peptide 1 (GLP-1) receptor agonists on the lowering of blood pressure is modest but significant when com- pared with other glucose-lowering agents and thus have exerted cardioprotective benefits.

A meta-analysis1 of 16 randomized controlled trials, including 2,417 control group participants and 3,443 patients enrolled in GLP-1 receptor agonist treatment, examined the blood pressure-lowering impact of exenatide and liraglutide.

Exenatide reduced systolic blood pressure (SBP) by a mean difference of −5.24 mm Hg compared with placebo (95% confidence interval [CI] −6.88 to −3.59, P < .001) and by −3.46 mm Hg compared with insulin glargine (95% CI −3.63 to −3.29, P < .001). In the exenatide-treated group, diastolic blood pressure (DBP) was reduced by −5.91 mm Hg compared with placebo (95% CI −7.53 to −4.28, P < .001) and by −0.99 mm Hg compared with sitagliptin (95% CI −1.12 to −0.87, P < .001).

For liraglutide, SBP changes in this meta-analysis were assessed in the groups treated with 1.2 mg/day or 1.8 mg/day of liraglutide. In the 1.2-mg/day group, liraglutide reduced SBP by a mean difference of −5.60 mm Hg compared with placebo (95% CI −5.84 to −5.36, P < .001) and by −2.38 mm Hg compared with glimepiride (95% CI −4.75 to −0.01, P = .05). In the 1.8-mg/day group, liraglutide also reduced SBP by −4.49 mm Hg compared with placebo (95% CI −4.73 to −4.26, P < .001) and by −2.62 mm Hg compared with glimepiride (95% CI −2.91 to −2.33, P < .001).

In summary, treatment with the GLP-1 receptor agonists exenatide and liraglutide reduced SBP and DBP by 1 to 5 mm Hg compared with antidiabetic drugs including insulin and glimepiride and with placebo for patients with type 2 diabetes mellitus. GLP-1 receptor agonists may offer an alternative therapy for these patients and will help provide additional cardiovascular benefits.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Wang B,
    2. Zhong J,
    3. Lin H, et al
    . Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15(8):737–749. doi:10.1111/dom.12085
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (12)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 12
1 Dec 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Reply: Antiobesity drug therapy
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In Reply: Antiobesity drug therapy
Yael Mauer, Marcie Parker, Sangeeta Kashyap
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 657-658; DOI: 10.3949/ccjm.88c.12002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Reply: Antiobesity drug therapy
Yael Mauer, Marcie Parker, Sangeeta Kashyap
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 657-658; DOI: 10.3949/ccjm.88c.12002
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Antiobesity drug therapy
  • Antiobesity drug therapy: An individualized and comprehensive approach
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
Show more Letters to the Editor

Similar Articles

Subjects

  • Obesity
  • Preventive Care
  • Rheumatology
  • Vascular Medicine
  • Mental Health
  • Geriatrics
  • Endocrinology
  • Drug Therapy

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire